The pharmaceutical company GW Pharmaceuticals has been testing a cannabis-based medication for a few years, and now they've announced their findings have proven the medication is effective in reducing the mortality rate of patients with glioblastoma multiforme, a brain cancer. Symptoms of the illness range from headaches to personality changes, and many diagnosed with it are only expected to live less than two years, but GW Pharmaceuticals suspects their medication is helping to expand this lifespan. CEO Justin Gover says, "We believe that the signals of efficacy demonstrated in this study further reinforce the potential role of cannabinoids in the field of oncology and provide GW with the prospect of a new and distinct cannabinoid product candidate in the treatment of glioma."
The results of the study, however, do not suggest that the cannabinoids are alone responsible for these results. In the trial phase, patients were given a combination of THC and CBD to supplement an oral chemotherapy drug called Temozolomide. Of the patients who received this mixture, 83% experienced a one-year survival rate, a large difference from the 53% survival rate of patients given placebo.
This information has been provided by Merry Jane and approved by our Chief Medical Officer.